UBS Group
LXEO icon

UBS Group’s Lexeo Therapeutics LXEO Stock Holding History

UBS Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Buy
354,044
+32,307
+10% +$175K ﹤0.01% 5285
2026
Q1 		$1.85M Buy
321,737
+40,654
+14% +$288K ﹤0.01% 5048
2025
Q4 		$2.79M Buy
281,083
+31,174
+12% +$284K ﹤0.01% 4644
2025
Q3 		$1.66M Sell
249,909
-21,995
-8% -$106K ﹤0.01% 5139
2025
Q2 		$1.09M Buy
271,904
+239,822
+748% +$789K ﹤0.01% 5381
2025
Q1 		$111K Sell
32,082
-18,972
-37% -$84K ﹤0.01% 6971
2024
Q4 		$336K Buy
51,054
+39,942
+359% +$315K ﹤0.01% 6118
2024
Q3 		$100K Buy
11,112
+7,983
+255% +$95.2K ﹤0.01% 6369
2024
Q2 		$50.2K Sell
3,129
-7,238
-70% -$105K ﹤0.01% 6687
2024
Q1 		$163K Buy
+10,367
New +$162K ﹤0.01% 5985

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

UBS Group's LXEO Position: Q2 2026 in Review

UBS Group increased its Lexeo Therapeutics (LXEO) stake by 10% in Q2 2026, buying an estimated $175K and bringing the position to 354,044 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #5285.

UBS Group first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.79M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • UBS Group held 354,044 shares of Lexeo Therapeutics worth $1.65M as of Q2 2026.
  • UBS Group bought 32,307 Lexeo Therapeutics shares in Q2 2026, an estimated $175K.
  • Lexeo Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5285 holding.
  • UBS Group first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • UBS Group's Lexeo Therapeutics position peaked at $2.79M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.